Novoprotein issued an announcement on November 1 addressing unusual stock trading fluctuations and risk warnings, stating that its AI-empowered high-throughput wet lab and data package services are still in the early stages of market expansion. As of the third quarter of 2026, revenue from these services accounted for less than 2% of the company's total revenue. The company noted that the application of AI in drug research and development remains in its infancy and faces risks including rapid technological iteration, lengthy industry validation cycles, and commercialization challenges. Future revenue and profit realization from these businesses carry significant uncertainty, and investors are advised to take a rational view and remain mindful of investment risks.